Ali Satvat (Menlo Park) joined KKR in 2012. He co-leads the Health Care industry team within KKR’s Americas Private Equity platform and serves as Global Head of KKR’s Health Care Strategic Growth platform. Mr. Satvat is a member of the Investment Committee and the Portfolio Management Committee for Americas Private Equity, chairs the Investment Committee and the Portfolio Management Committee for Health Care Strategic Growth, and manages KKR’s controlling interest in HealthCare Royalty Partners. He has served on various private and public boards of directors, including most recently BlueSprig, BridgeBio Pharma, Cordis, Geode Health, Precipart, SkinSpirit, SunFire, and Treeline Biosciences, and has been actively involved with historical and/or exited KKR investments such as Ajax Health, Arbor Pharmaceuticals, Aurion Biotech, Coherus Oncology, Cortex, Eidos Therapeutics, EPIX Therapeutics, Falcon Vision, Gland Pharma, Headlands Research, PRA Health Sciences, Sapphiros, Slayback Pharma, Spirox, Trilogy MedWaste, and Zeus Health. Prior to joining KKR, Mr. Satvat was a principal with Apax Partners, where he focused on health care private equity and growth equity investments. Previously, he held various positions with Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He previously served as a member of the board of directors of the Healthcare Private Equity Association and has been involved in a number of non-profit organizations.